HET tumors more commonly showed a decreasing trend in HER2 expression (5/9, 55.6%) compared with non-HET cases (17/40, 42.5%), and only 1 patient had an increase in HER2 IHC score in posttreatment tissue ( Figure 3, A and B ).
← all excerpts
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
1
—
—